Tags

Type your tag names separated by a space and hit enter

Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
J Obstet Gynaecol Res. 2004 Aug; 30(4):297-302.JO

Abstract

AIM

The influence of hormone replacement therapy (HRT) on breast cancer has not been clarified in Japan, however the Women's Health Initiative (WHI) trial recently showed breast cancer risk according to use of estrogen plus progestin. We assessed retrospectively the incidence of breast cancer in postmenopausal women who received HRT at our outpatients clinic.

METHODS

Among the patients registered at the postmenopausal clinic in Kyushu University Hospital from 1990 to 2003, 917 women who received HRT (estrogen plus progestin, 507 patients; estrogen only, 410 patients) after informed consent were examined by mammography or breast ultrasound tomography.

RESULTS

Breast cancer occurred in nine patients: five patients who received estrogen plus progestin and four who received estrogen only. Four of five the patients who used estrogen plus progestin received HRT for more than 5 years.

CONCLUSION

Breast cancer risk in patients who used estrogen plus progestin for more than 5 years seemed to be higher than those who used it for less than 5 years. This tendency is similar to the results of the WHI. In addition, breast cancer incidence in patients treated with HRT in our clinic seemed to be higher than the incidence in average Japanese women. Therefore, patients need to be given sufficient information before undergoing HRT.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. nozaki@med.kyushu-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15238106

Citation

Nozaki, Masahiro, et al. "Hormone Replacement Therapy and Breast Cancer Risk in Kyushu University Hospital: Supporting the Women's Health Initiative Study." The Journal of Obstetrics and Gynaecology Research, vol. 30, no. 4, 2004, pp. 297-302.
Nozaki M, Koera K, Nagata H, et al. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study. J Obstet Gynaecol Res. 2004;30(4):297-302.
Nozaki, M., Koera, K., Nagata, H., & Nakano, H. (2004). Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study. The Journal of Obstetrics and Gynaecology Research, 30(4), 297-302.
Nozaki M, et al. Hormone Replacement Therapy and Breast Cancer Risk in Kyushu University Hospital: Supporting the Women's Health Initiative Study. J Obstet Gynaecol Res. 2004;30(4):297-302. PubMed PMID: 15238106.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study. AU - Nozaki,Masahiro, AU - Koera,Keiko, AU - Nagata,Hideaki, AU - Nakano,Hitoo, PY - 2004/7/9/pubmed PY - 2004/11/16/medline PY - 2004/7/9/entrez SP - 297 EP - 302 JF - The journal of obstetrics and gynaecology research JO - J. Obstet. Gynaecol. Res. VL - 30 IS - 4 N2 - AIM: The influence of hormone replacement therapy (HRT) on breast cancer has not been clarified in Japan, however the Women's Health Initiative (WHI) trial recently showed breast cancer risk according to use of estrogen plus progestin. We assessed retrospectively the incidence of breast cancer in postmenopausal women who received HRT at our outpatients clinic. METHODS: Among the patients registered at the postmenopausal clinic in Kyushu University Hospital from 1990 to 2003, 917 women who received HRT (estrogen plus progestin, 507 patients; estrogen only, 410 patients) after informed consent were examined by mammography or breast ultrasound tomography. RESULTS: Breast cancer occurred in nine patients: five patients who received estrogen plus progestin and four who received estrogen only. Four of five the patients who used estrogen plus progestin received HRT for more than 5 years. CONCLUSION: Breast cancer risk in patients who used estrogen plus progestin for more than 5 years seemed to be higher than those who used it for less than 5 years. This tendency is similar to the results of the WHI. In addition, breast cancer incidence in patients treated with HRT in our clinic seemed to be higher than the incidence in average Japanese women. Therefore, patients need to be given sufficient information before undergoing HRT. SN - 1341-8076 UR - https://www.unboundmedicine.com/medline/citation/15238106/Hormone_replacement_therapy_and_breast_cancer_risk_in_Kyushu_University_Hospital:_supporting_the_Women's_Health_Initiative_study_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1341-8076&date=2004&volume=30&issue=4&spage=297 DB - PRIME DP - Unbound Medicine ER -